What peptide is comparable to retatrutide?

The closest relatives are other multi-receptor incretin peptides. Tirzepatide acts on two of retatrutide’s three receptors, GIP and GLP-1, without glucagon. Survodutide, from Boehringer Ingelheim, and mazdutide, from Innovent, pair GLP-1 with glucagon receptor activity in late-stage trials. Retatrutide (GLP-3R) adds all three, which makes it the reference point for how far weight loss in trials can go.

Eloralintide is comparable in results, not mechanism. At 48 weeks, its phase 2 trial reached 20.1% weight loss at 9 mg, while retatrutide’s reached 24.2% at 12 mg, in separate trials with different designs. Labs testing whether amylin and incretin signals add up need both kinds of compound. See our eloralintide vs GLP-3R comparison. Shop eloralintide.